Psychopharmacology and psychiatry
Nov 20, 2026
•
4 min read
Amphetamine ceilings up about 31% to 40%, methylphenidate about 19%. Whether pharmacies see it depends on manufacturers.
Nov 13, 2026
3 min read
Two Phase 3 wins, modest effect sizes, and a DEA step still ahead.
Nov 6, 2026
What the DEA's October 2026 interim final rule means for prescribing access amid the ongoing stimulant shortage.
Oct 30, 2026
Motivista's 510(k) clearance covers negative symptoms of schizophrenia, an indication no drug holds in the US.
Oct 23, 2026
A TARPγ8-selective AMPA modulator challenges dopamine-centered antimanic pharmacology.
Oct 16, 2026
Weltruza skips post-injection monitoring; Elixir Sulfanilamide explains why that still needs scrutiny.